Table 1. | Patient, examination and treatment variables |
| N | Mean (SD) | Range | ||
|---|---|---|---|---|
| Age at surgery | ||||
| Years | 19 | 22.2 (5.6) | 16.1 - 32.6 | |
| Gender | ||||
| Male | 2 (11%) | - | - | |
| Female | 17 (89%) | - | - | |
| TMJ involvement | ||||
| Unilateral | 4 (21%) | - | - | |
| Bilateral | 15 (79%) | - | - | |
| Antirheumatic medication | ||||
| No medication | 6 | - | - | |
| NSAID mono | 4 | - | - | |
| MTX mono | 5 | - | - | |
| NSAID + TMJ steroid | 1 | - | - | |
| Biologics + MTX | 1 | - | - | |
| Biologics + MTX + NSAID | 1 | - | - | |
|
Biologics + MTX + NSAID + TMJ steroid |
1 | - | - | |
| Total | 19 | - | - | |
| Timing of examinations (months) | ||||
| T1 | Anamnestic and clinical | 17 | 31.9 (18.3) | 6.3 - 69.7 |
| Radiologic | 16 | 5 (5.6) | 0.2 - 15.8 | |
| T2 | Anamnestic and clinical | 14 | 10.3 (5.7) | 1 - 20 |
| Radiologic | 16 | 0.9 (1.7) | 0.2 - 6.2 | |
| T3 | Anamnestic and clinical | 16 | 45.8 (22.6) | 14.1 - 93 |
| Radiologic | 11 | 31.2 (20.4) | 9.6 - 68 | |
| Surgical treatment | ||||
| Genioplasty | 2 | - | - | |
| Le Fort I | 3 | - | - | |
| Le Fort I + genioplasty | 1 | - | - | |
| Le Fort I + BSSO | 6 | - | - | |
| Le Fort I + BSSO + genioplasty | 4 | - | - | |
| BSSO | 1 | - | - | |
| BSSO + genioplasty | 2 | - | - | |
| Total | 19 | - | - | |
N = number of patients; SD = standard deviation; NSAID = nonsteroidal anti-inflammatory drugs; MTX = methotrexate; TMJ = temporomandibular joint; TMJ steroid = intraarticular steroid injection in TMJ; T1 = preoperative examination; T2 = postoperative examination; T3 = long-term examination; BSSO = bilateral sagittal split osteotomy. |
.png)
.png)
.png)